1630P A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC).

MLA

Van Wilpe, S., et al. “1630P A Multicenter Retrospective Study on the Efficacy of Anti-PD-(L)1 in Microsatellite Unstable (MSI-H) Metastatic Castrate-Resistant Prostate Cancer (MCRPC).” Annals of Oncology, vol. 35, Sept. 2024, p. S984. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.08.1711.

APA

Van Wilpe, S., Taha, T., Rothmann, E., Altshuler, E., Ledet, E., Bergman, A. M., Tsantoulis, P., Oldenburg, J., Bernard-Tessier, A., Robbrecht, D., Bruijnen, C., Van Der Hulle, T., Antonarakis, E. S., Rothermundt, C. A., Omlin, A. G., Sartor, O., Sena, L., Beltran, H., de Bono, J. S., & Mehra, N. (2024). 1630P A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology, 35, S984. https://doi.org/10.1016/j.annonc.2024.08.1711

Chicago

Van Wilpe, S., T. Taha, E. Rothmann, E. Altshuler, E. Ledet, A.M. Bergman, P. Tsantoulis, et al. 2024. “1630P A Multicenter Retrospective Study on the Efficacy of Anti-PD-(L)1 in Microsatellite Unstable (MSI-H) Metastatic Castrate-Resistant Prostate Cancer (MCRPC).” Annals of Oncology 35 (September): S984. doi:10.1016/j.annonc.2024.08.1711.